BUZ INVESTORS Dr. Lawrence E. Samuels Omni Health, Inc. ( OTC PINK : OMHE ), a vertically integrated healthcare company

Omni Health Inc. (OMHE) Adds Dr. Lawrence E. Samuels To Scientific Advisory Board

|Chart | Calendar   | TRADE NOW | CANNABIS

Omni Health, Inc. Expands Scientific Advisory Board, Adds Dr. Lawrence E. Samuels

 

BUZ INVESTORS PRESS RELEASE  Dr. Lawrence E. Samuels Omni Health, Inc. ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, announced that Lawrence E. Samuels, MD, has joined its Scientific Advisory Board (SAB). The SAB will work closely with the OMHE management team to advance the Company’s product development programs. “We’re honored that Dr. Samuels, a renowned inventor & scientist has chosen to serve on our Scientific Advisory board,” said Andrey Soloviev, OMHE’s Chief Executive Officer. “His ongoing technical expertise and innovative guidance will allow us to move strategically with our resources and accelerate development of our early-stage pipeline products to run parallel to our existing business.”

Dr. Lawrence E. Samuels, the chief of dermatology at St. Luke’s Hospital in St. Louis and a widely-respected leader in his medical field, founded RX Systems PF in 1966 and is highly knowledgeable in pH-balanced, Glypoic Complex-based products, retinols and moisturizers for the face and body, anti-aging, skin care and hair repair products. Dr. Samuels will provide access to a lucrative niche market of doctors’ offices and medical facilities.

Dr. Samuels is a member of the teaching faculty at Washington University Medical School and he has provided expert dermatological care for more than three decades. He’s a board-certified dermatologist and a member of the American Academy of Dermatology and the American Society for Dermatologic Surgery.



Dr. Lawrence E. Samuels

The global wellness products industry is currently a $569 billion industry, and anti-aging is one of the fastest growing categories. The market research firm Global Industry Analysts estimates that a boomer fueled consumer base “seeking to keep the dreaded signs of aging at bay” will push US market for anti-aging products from about $80 billion now to more than $114 billion by 2020. Anti-aging skincare is one of the industry’s booming sectors.

CEO Andrey Soloviev further noted, “Our plan for growth accelerates with the synergy created by our scientific board, our current/future product lines and our existing pharmacy which has been operating for 41 years. With Dr. Samuels’ expertise, we expect to innovate, develop multiple lines of products beginning with our flagship skincare line.”

For more information about Omni Health, go to www.OmniHealth.md

About Omni Health Inc.
Omni Health, Inc. ( OTC PINK : OMHE ) is a 41 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.

Business Description

Industry: Retail – Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare: NAS:(CJJD), OTCPK:(HEWA), OTCBB:(COCP), NYSE:(GNC), NAS:(PETS), OTCPK:(CLCGY), OTCPK:(JCOUF), NYSE:(RAD), NAS:(WBA) » details
Headquarter Location: USA

Omni Health Inc is a pharmaceutical company operating in Hialeah, Florida, Malecon Pharmacy. It provides healthcare products, pharmacy operations, prescription drugs and other services and products in skin care and anti-aging industry.

 

 

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Featured Video Play Icon

Dr Dreisinger on extraction technologies for Rare Earths

Dr Dreisinger on extraction technologies for Rare Earths

Buz Investors extraction technologies David Dreisinger, Director and VP of Metallurgy for Search Minerals Inc. (TSXV: SMY), in an interview with InvestorIntel’s CEO Tracy Weslosky discuss the company’s rare earth

Buz Investors extraction technologies David Dreisinger, Director and VP of Metallurgy for Search Minerals Inc. (TSXV: SMY), in an interview with InvestorIntel’s CEO Tracy Weslosky discuss the company’s rare earth extraction patent. The rare-earth-carrying minerals found in their deposits in Newfoundland and Labrador (Allanite and Fergusonite) are highly reactive to acid. This feature greatly simplifies the extraction process by cutting out the labor and facility demanding technique of flotation, gravity, and magnetic separation. Additionally, this ease of extraction means that they can scale to the right size and meet market demands.



Other Stories Buz Traders Follow

extraction technologies

Tracy Weslosky: David, I understand that you are considered one of the top rare earth experts in the world. To confirm you have 21 patents?

David Dreisinger: Yes, I have 21 U.S. patents in different areas including the Search Minerals patent.

Tracy Weslosky: Please share a little bit about the Search Minerals’ patent with our audience.

David Dreisinger: What we figured out Tracy is that our Foxtrot Deposit in Labrador has 2 types of minerals, Allanite and Fergusonite minerals, that carry our rare earths, which are quite reactive with acid. We have figured out a way to directly extract our rare earths from our minerals without having to go through the usual steps of grinding, flotation, gravity and magnetic separation. We directly treat the mineral, cover the rare earths in the solution and we come out with a rare earth product that goes directly to the refinery.

Tracy Weslosky: David, could you clarify this for me and for our InvestorIntel audience members that don’t fully understand this patent. Obviously this is a competitive advantage for Search Minerals, yes?

David Dreisinger: It’s a huge advantage for us because we have the ability to scale to the right size to meet the market. We are planning 1,000 tons a day of ore treatment. We don’t have to build a huge mineral processing facility. We can directly treat the ore, and go through to this mix rare earth oxide. We are located on tidewater in Labrador and have good infrastructure around us. We have a low capital cost and a reasonable operating cost. We are well positioned to hit the rare earth market as it matures and grows in the years ahead.

Tracy Weslosky: For everyone out there in InvestorIntel that may not be familiar with Search Minerals, this is a company that anyone interested in sustainability is going to love.


Ebates Coupons and Cash Back



Commodities ( Gold ) ( Silver ) ( Lithium )




Featured Video Play Icon

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX |OTCQX: IGXT), discusses the recent deal with Eli Lilly to manufacture Tadalafil (also known as Cialis®) as a pharmaceutical oral film, using IntelGenx’s VersaFilm™ technology. IntelGenx’s tadalafil oral film offers an improved discrete dosage form that does not require water intake. Dr. Zerbe states that this deal is significant because moving forward potential partner licensees will not face any litigation after completing a deal with IntelGenx, making the launch and commercialization of a VersaFilm™ partnered product extremely easy.

 

Major Aerospace Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )